TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31641948

Group type: EXPERIMENTAL
Intervention: Fong's clinical risk score (CRS) as a categorical variable (CRS 0-1 vs. 2-3 vs. 4-5)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Polymorphonuclear neutrophil (PMN) count (> 6000/mm3 vs. ≤ 6000/mm3) before chemotherapy
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Fong's clinical risk score (CRS)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: FOLFOX-based chemotherapy regimen
Number of subjects: 181
Study: 30472022

Group type: EXPERIMENTAL
Intervention: Multimodal telemonitoring for 6 months
Number of subjects: 306

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 306
Study: 26922634

Group type: EXPERIMENTAL
Intervention: Irrigation with drinking tap water using a Monoject® Curved 412 Tip Syringe
Number of subjects: 280

Group type: COMPARATOR
Intervention: Standard postoperative instructions without irrigation
Number of subjects: 280
Study: 25495134

Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg and famotidine 26.6 mg
Number of subjects: 86
Study: 22707006

Group type: EXPERIMENTAL
Intervention: TVT
Number of subjects: 280

Group type: COMPARATOR
Intervention: TVT Secur
Number of subjects: 280
Study: 21720594

Group type: EXPERIMENTAL
Intervention: Augmented retrograde intramedullary (IM) nail fixation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Augmented periarticular locking‐plate fixation
Number of subjects: 20
Study: 19690792

Group type: EXPERIMENTAL
Intervention: Group pelvic floor muscle training (PFMT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Individual pelvic floor muscle training (PFMT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both group and individual PFMT
Number of subjects: 60
Study: 16893694

Group type: EXPERIMENTAL
Intervention: Biolimus A9 drug-eluting stent
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control uncoated stent
Number of subjects: 120
Study: 15082989

Group type: EXPERIMENTAL
Intervention: Overall opioid use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxycodone or hydrocodone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propoxyphene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health insurance status and geographic regions
Number of subjects: 0
Study: 11748361

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid samples from patients with aneurysmal SAH
Number of subjects: 19
Study: 9290452

Group type: EXPERIMENTAL
Intervention: 25 micrograms of misoprostol
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: 50 micrograms of misoprostol
Number of subjects: 399
Study: 8222513

Group type: COMPARATOR
Intervention: D-glucose infusion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Arginine vasopressin infusion
Number of subjects: 6
Study: 3951807

Group type: EXPERIMENTAL
Intervention: Half-dose Amicar (50 mg/kg every four hours for five days, up to a maximum of 30 g/day)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Full-dose Amicar (100 mg/kg every four hours, up to a maximum of 30 g/day)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Both groups (Half-dose and Full-dose)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Both dose levels of Amicar
Number of subjects: 59

Group type: COMPARATOR
Intervention: Prior aspirin ingestion
Number of subjects: 59
Study: 29557487

Group type: EXPERIMENTAL
Intervention: TEAS (Transcutaneous Electrical Acupoint Stimulation)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (Tramadol hydrochloride tablets)
Number of subjects: 120
Study: 29750367

Group type: EXPERIMENTAL
Intervention: Choline supplementation (2 g daily)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 25649051

Group type: EXPERIMENTAL
Intervention: 5 mg OPC
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 15 mg OPC
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 30 mg OPC
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 25012176

Group type: EXPERIMENTAL
Intervention: rt-PA/heparin (1 mg per lumen, once per week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: heparin alone (thrice-weekly)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rt-PA/heparin
Number of subjects: 0
Study: 22654433

Group type: EXPERIMENTAL
Intervention: HER2 positive gastric cancer patients with liver metastases
Number of subjects: 84

Group type: COMPARATOR
Intervention: HER2 negative gastric cancer patients with liver metastases
Number of subjects: 84
Study: 19523170

Group type: EXPERIMENTAL
Intervention: Pseudocatalase cream with NB‐UVB
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo with NB‐UVB
Number of subjects: 32
Study: 17035933

Group type: EXPERIMENTAL
Intervention: Continuous paroxetine treatment
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Intermittent paroxetine treatment (luteal phase only)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 16304269

Group type: EXPERIMENTAL
Intervention: IV azithromycin plus IV ceftriaxone followed by oral azithromycin
Number of subjects: 163

Group type: COMPARATOR
Intervention: IV levofloxacin followed by oral levofloxacin
Number of subjects: 163
Study: 11986110

Group type: EXPERIMENTAL
Intervention: travoprost 0.0015%
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: travoprost 0.004%
Number of subjects: 605

Group type: COMPARATOR
Intervention: timolol 0.5%
Number of subjects: 605
Study: 9607375

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 50
Study: 7612039

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Calcium
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Low-dose corticosteroids
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Overall RA group
Number of subjects: 106
Study: 1643914

Group type: EXPERIMENTAL
Intervention: Pulsed-release albuterol sulfate (8 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6383749

Group type: EXPERIMENTAL
Intervention: Gentamicin 2.4 mg/kg at 12‐ or 18‐hour dosing intervals
Number of subjects: 22
Study: 31037845

Group type: EXPERIMENTAL
Intervention: PrEP initiation within four weeks
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: PrEP retention at four weeks
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Distance to clinic ≥2 km
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Eligibility during home-based testing without same-day PrEP start
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Barriers to PrEP use
Number of subjects: 701
Study: 29374469

Group type: EXPERIMENTAL
Intervention: Propofol/remifentanil (4-6 mg/kg/h)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Sevoflurane/remifentanil (approx. 2.2 vol% endtidal)
Number of subjects: 54
Study: 27310330

Group type: EXPERIMENTAL
Intervention: PTC299 (0.03 to 3 mg/kg single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PTC299 (0.3 to 1.2 mg/kg twice a day or 1.6 mg/kg 3 times a day for 7 days)
Number of subjects: 0
Study: 25623098

Group type: EXPERIMENTAL
Intervention: R3 thoracic sympathicotomy
Number of subjects: 200

Group type: COMPARATOR
Intervention: R3 thoracic sympathicotomy plus bypass fiber resection (R3+)
Number of subjects: 200
Study: 22404324

Group type: EXPERIMENTAL
Intervention: Levofloxacin (therapeutic dose 750 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Levofloxacin (low dose 7.5 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cyclosporine (therapeutic dose 200 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cyclosporine (low dose 2 mg)
Number of subjects: 16
Study: 19961902

Group type: EXPERIMENTAL
Intervention: Nicotine gum (6 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 18675294

Group type: EXPERIMENTAL
Intervention: Cognitive perception information curriculum
Number of subjects: 2734

Group type: EXPERIMENTAL
Intervention: Cognitive perception information + behavioral skills curriculum
Number of subjects: 2734

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 2734

Group type: EXPERIMENTAL
Intervention: Cognitive perception information curriculum and Cognitive perception information + behavioral skills curriculum
Number of subjects: 2734
Study: 16192259

Group type: EXPERIMENTAL
Intervention: Meal replacements
Number of subjects: 92

Group type: COMPARATOR
Intervention: Orlistat
Number of subjects: 92
Study: 12856809

Group type: EXPERIMENTAL
Intervention: Compound Nylestriol Tablet (CNT) - 0.5 mg nylestriol and 0.15 mg levonorgestrel, one tablet per week for one year
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study: 10941861

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Manipulative techniques
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (placebo needle application)
Number of subjects: 43
Study: 7851278

Group type: EXPERIMENTAL
Intervention: Buprenorphine (high-dose, 3 day regimen)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Clonidine (standard 5-day course)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 25
Study: 2682412

Group type: EXPERIMENTAL
Intervention: Patient-controlled administration of 10 mg meperidine every 20 minutes
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nurse-administered meperidine (25-50 mg every 3 hours as requested)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Patient-controlled administration of meperidine
Number of subjects: 64
Study: 338400

Group type: EXPERIMENTAL
Intervention: 30 mg daily of maprotiline (Ludiomil) administered once or thrice daily
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: 75 mg daily of maprotiline (Ludiomil) administered once or thrice daily
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: 25 mg three times daily of maprotiline (Ludiomil)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: 10 mg thrice daily of maprotiline (Ludiomil)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: 30 mg nocte of maprotiline (Ludiomil)
Number of subjects: 191
Study: 31915160

Group type: EXPERIMENTAL
Intervention: 300 mg lithium carbonate
Number of subjects: 160

Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 160
Study: 30930360

Group type: EXPERIMENTAL
Intervention: Clinical scoring model based on predictors associated with mortality (anemia, tuberculous meningitis, severe pneumonia, hypoalbuminemia, unexplained infections or space‐occupying lesions, malignancies)
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Clinical scoring model categorized into low-risk (0-2 points) and high-risk (4-16 points) groups
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Kaplan-Meier curve analysis
Number of subjects: 1007
Study: 28366730

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 166

Group type: COMPARATOR
Intervention: Loop electrosurgical excision procedure
Number of subjects: 166
Study: 25855884

Group type: EXPERIMENTAL
Intervention: Calfactant administration
Number of subjects: 317

Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 317
Study: 23765945

Group type: EXPERIMENTAL
Intervention: B-vitamins (folic acid, 2 mg; vitamin B6, 25 mg; vitamin B12, 500 μg)
Number of subjects: 8164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8164

Group type: EXPERIMENTAL
Intervention: B-vitamins
Number of subjects: 8164
Study: 21147261

Group type: EXPERIMENTAL
Intervention: Warfarin continuation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Warfarin interruption
Number of subjects: 100
Study: 18678567

Group type: EXPERIMENTAL
Intervention: Spontaneous pursed lips breathing
Number of subjects: 32

Group type: COMPARATOR
Intervention: Prevented spontaneous pursed lips breathing (using a mouthpiece)
Number of subjects: 32
Study: 17202604

Group type: EXPERIMENTAL
Intervention: Sucrose (20 percent)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Non‐nutritive sucking (NNS)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Rocking
Number of subjects: 104

Group type: COMPARATOR
Intervention: Distilled water (DW)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Expressed breast milk (EBM)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Massage
Number of subjects: 104
Study: 12744410

Group type: EXPERIMENTAL
Intervention: PMRC/RC open sandwich restoration
Number of subjects: 57

Group type: COMPARATOR
Intervention: RC control restoration
Number of subjects: 57
Study: 10948387

Group type: EXPERIMENTAL
Intervention: Reduced-fat blind (RFB)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Reduced-fat informed (RFI)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Reduced-fat informed with details (RFID)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Full-fat blind (FFB)
Number of subjects: 279
Study: 8832308

Group type: EXPERIMENTAL
Intervention: Epidural buprenorphine (4 micrograms/kg body weight)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Epidural clonidine (3 micrograms/kg body weight)
Number of subjects: 20
Study: 8174496

Group type: EXPERIMENTAL
Intervention: Cefazolin (1 g q 8 h i.v.)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Cefuroxime (1.5 g single dose)
Number of subjects: 496
Study: 3804901

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 48
Study: 28576557

Group type: EXPERIMENTAL
Intervention: Ethanol lock therapy (ELT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard of care with saline heparin locks (Control)
Number of subjects: 38
Study: 27423921

Group type: EXPERIMENTAL
Intervention: Exercise intervention (12 week, three times per week progressive exercise program including aerobic and strengthening exercises)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 32
Study: 24470182

Group type: EXPERIMENTAL
Intervention: EPA-rich supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DHA-rich supplementation
Number of subjects: 0
Study: 22320849

Group type: EXPERIMENTAL
Intervention: Baseline oral health-related knowledge, attitudes, and beliefs regarding caries control.
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Concern about getting decay in one's own teeth.
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Knowledge about mother's cavities.
Number of subjects: 493
Study: 19474006

Group type: EXPERIMENTAL
Intervention: Motor control exercise
Number of subjects: 34

Group type: COMPARATOR
Intervention: General exercise
Number of subjects: 34

Group type: COMPARATOR
Intervention: Spinal manipulative therapy
Number of subjects: 34
Study: 18302125

Group type: EXPERIMENTAL
Intervention: Teacher-directed program (T-D)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Combined program (T-D + CAI)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Computer-assisted instructional (CAI) program
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no cognitive strategies training)
Number of subjects: 44
Study: 15996346

Group type: EXPERIMENTAL
Intervention: Allergy Guard (topical cream containing zinc gel)
Number of subjects: 0
Study: 11812552

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors
Number of subjects: 31402
Study: 10343146

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d. and amoxicillin 1,000 mg b.i.d. for 7 days
Number of subjects: 61
Study: 8613276

Group type: EXPERIMENTAL
Intervention: Community-based education classes (4 classes in the first 6 months and 4 classes in the next year)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Community-based education classes (2 classes)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Community-based education classes
Number of subjects: 111
Study: 1894479

Group type: EXPERIMENTAL
Intervention: Dioptic stimuli (identical to both eyes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dichoptic stimuli (differed between the two eyes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Random variations in display contrast
Number of subjects: 0
Study: 6807149

Group type: EXPERIMENTAL
Intervention: DSGL+ by Spinhaler
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: DSGL- by Spinhaler
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: DSGN nebulized solution
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 29102588

Group type: EXPERIMENTAL
Intervention: Weight loss diet of less fat and carbohydrates
Number of subjects: 62

Group type: COMPARATOR
Intervention: No dietary limitations (Control group)
Number of subjects: 62
Study: 30256894

Group type: EXPERIMENTAL
Intervention: Whole grain-enriched diet
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 123
Study: 27402619

Group type: EXPERIMENTAL
Intervention: Rank‐ordered calorie labels plus a statement on energy needs per meal (CL)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Rank‐ordered exercise labels showing minutes of brisk walking necessary to burn the food calories (EL)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Menus with no labels (NL)
Number of subjects: 372
Study: 25119950

Group type: EXPERIMENTAL
Intervention: Varilrix(®) + cyclosporine (2.5 mg/kg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Subcutaneous saline + cyclosporine (2.5 mg/kg/day)
Number of subjects: 24
Study: 21127282

Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 220

Group type: COMPARATOR
Intervention: Midazolam infusion
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 220
Study: 19643842

Group type: EXPERIMENTAL
Intervention: Timing and Coordination (TC)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Walking, Endurance, Balance, and Strength (WEBS)
Number of subjects: 50
Study: 17919215

Group type: EXPERIMENTAL
Intervention: 0.1 mL intradermal 1% lignocaine
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: ethyl chloride
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: entonox (50:50 oxygen : nitrous oxide)
Number of subjects: 300

Group type: COMPARATOR
Intervention: no anaesthesia
Number of subjects: 300
Study: 15449549

Group type: EXPERIMENTAL
Intervention: Octreotide administration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 20
Study: 11524188

Group type: EXPERIMENTAL
Intervention: Vitrectomy (n = 21 eyes)
Number of subjects: 25

Group type: COMPARATOR
Intervention: No Vitrectomy (n = 20 eyes)
Number of subjects: 25
Study: 9745451

Group type: EXPERIMENTAL
Intervention: Spironolactone (MR antagonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spironolactone (two doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7836162

Group type: EXPERIMENTAL
Intervention: 10% glucose solution containing 6‐[3H]glucose (CHO)
Number of subjects: 6
Study: 2831524

Group type: EXPERIMENTAL
Intervention: Atenolol (10 mg IV every six hours for three days, then 100 mg orally once a day for four days)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 29580733

Group type: EXPERIMENTAL
Intervention: Completion axillary lymph node dissection (cALND)
Number of subjects: 4331

Group type: COMPARATOR
Intervention: Sentinel lymph node biopsy (SLNB) only
Number of subjects: 4331
Study: 28335809

Group type: EXPERIMENTAL
Intervention: Online active learning module, direct electronic access to specialist advice, and performance feedback. Engagement strategies included multiple rounds of invitations, pre-notification, rewards, and incentives.
Number of subjects: 146
Study: 25906983

Group type: EXPERIMENTAL
Intervention: Robot-assisted fingers training
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (non-assisted fingers training)
Number of subjects: 19
Study: 23090678

Group type: EXPERIMENTAL
Intervention: 2.5 mg daily oral ibandronate (n = 40)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 20 mg intermittent oral ibandronate (n = 34)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Oral placebo (n = 36)
Number of subjects: 110
Study: 20380480

Group type: EXPERIMENTAL
Intervention: Fosamprenavir/ritonavir (FPV/r) 1400 mg/100 mg
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (ATV/r) 300 mg/100 mg
Number of subjects: 106
Study: 18652000

Group type: EXPERIMENTAL
Intervention: Standard education plus addition of a video
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard pre-chemotherapy education
Number of subjects: 0
Study: 16861368

Group type: EXPERIMENTAL
Intervention: Coping with caregiving class (CWC)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Enhanced support group (ESG)
Number of subjects: 213
Study: 15006249

Group type: COMPARATOR
Intervention: Phytoestrogens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Black cohosh
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors
Number of subjects: 0
Study: 10832917

Group type: EXPERIMENTAL
Intervention: Ondansetron (4 microg/kg twice a day) + Naltrexone (25 mg twice a day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9093956

Group type: EXPERIMENTAL
Intervention: Visual function tests (including visual acuity, contrast sensitivity, mean deviation, and color vision)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Self-reported vision assessment
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Questionnaire on visual tasks in daily living
Number of subjects: 438
Study: 8475558

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 infusion (PG group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 20
Study: 2881461

Group type: EXPERIMENTAL
Intervention: HSR-902 (30 mg daily for 7 days)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Butylscopolamine bromide (60 mg daily for 7 days)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: HSR-902
Number of subjects: 170

Group type: COMPARATOR
Intervention: Butylscopolamine bromide
Number of subjects: 170
Study: 31408387

Group type: EXPERIMENTAL
Intervention: Reflection practice
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Collaborative learning
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Passive acquisition of knowledge
Number of subjects: 129

Group type: COMPARATOR
Intervention: Reflection practice, Collaborative learning, Passive acquisition of knowledge
Number of subjects: 129